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Introduction
The  placenta  grows  rapidly  and  exhibits  marked 
changes in morphological structure according to fetal de-
velopment. Although the placenta is a temporary organ, it 
is an interface between the dam and developing embryos/
fetuses and a multifaceted organ  that performs a number of 
important functions that are modified throughout gestation. 
These functions include anchoring the developing fetus to 
the uterine wall, mediating maternal immune tolerance, O2/
CO2 exchange, providing nutrients for the fetus and remov-
ing waste products during embryonic development1. It also 
secures the embryo/fetus to the endometrium as a protective 
barrier against xenobiotics and releases a variety of steroids, 
hormones and cytokines. Therefore, placental dysfunction 
and injury have adverse effects on the maintenance of preg-
nancy, and fetal growth and development. Drug- or chemi-
cal-induced histopathological changes of the placenta in rats 
are important in safety evaluation to understand the mecha-
nism of teratogenicity and developmental toxicity. Howev-
er, the placenta has not received proper consideration as a 
target organ in safety evaluation of the risks for dams and 
embryos/fetuses. Morphological or histopathological evalu-
ation of placental development and abnormalities has been 
scarce and incomplete in experimental animals. The pres-
ent review describes an overview of the normal placental 
structure and the histopathology of some drug- or chemical-
induced placental lesions and the relationship between fetal 
intrauterine growth restriction (IUGR) and a small placenta 
in rats.
Placentation in Mammals
In mammals, a yolk sac placenta and chorioallantoic 
placenta, are present during gestation. The yolk sac actively 
absorbs  nutrients  from  the  chorion  and  chorionic  cavity, 
transports them to the embryo through the yolk sac circula-
tion, and plays a role as a transient placenta during early 
post-implantation before the allantoic circulation is estab-
lished2,3. In most mammals including humans, the yolk sac 
placenta becomes vestigial after the first trimester. On the 
other hand, the inverted yolk sac eventually covers the fetus 
and contributes to the special functions as a yolk sac placen-
ta before parturition in rodents and rabbits. The chorioal-
lantoic placenta is the principal placenta in mammals during 
middle to late-gestation and is formed from the endometri-
um of the dam and the trophectoderm of the embryo. The 
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definitive chorioallantoic placenta shows a variety of dif-
ferent shapes between species4, such as diffuse (horse, pig), 
discoid (human, rodent), zonary (dog, cat) and multicoty-
ledonary (cow, sheep). Furthermore, the three main types 
are  recognized  according  to  the  relationship  established 
between the chorion and uterine wall5,6: (1) epitheliochorial 
type (horse, pig, cow), (2) endotheliochorial type (dog, cat) 
and (3) hemochorial type (human, rodent; Fig. 1).
Normal Development and Structure of the  
Chorioallantoic Placenta in Rats
The rat chorioallantoic placenta morphologically has a 
discoid shape and is classified into the hemochorial type. 
Histologically, the maternal part of the placenta consists of 
the decidua and metrial gland. The fetal part of the placenta 
consists of the labyrinth zone and basal zone (Fig. 2). In ad-
dition, there are two distinct layers of membranes that en-
close the fetus. The outer layer is the yolk sac, and the inner 
layer is the amnion.
Development of the chorioallantoic placenta
The trophectoderm, which differentiates into the pla-
centa, consists of the mural trophectoderm and polar troph-
ectoderm (Fig. 2). The mural trophectoderm surrounding 
the blastocyst cavity arrests cell division and differentiates 
into primary trophoblastic giant cells just after implanta-
tion. The polar trophectoderm neighboring the embryoblast 
forms the ectoplacental cone and invades into the decidua 
(Figs. 3, 4). The edge and center of the ectoplacental cone 
differentiate into (secondary) trophoblastic giant cells and 
spongiotrophoblasts, respectively, and then these cell mass-
es form the basal zone7. The chorion, which is the embryon-
ic-side membrane of the ectoplacental cone, fuses with the 
allantois derived from the embryonic hindgut and then dif-
ferentiates into the labyrinth zone. In the endometrium, the 
decidual cells develop from the endometrial stromal cells 
by stimulation of blastocyst apposition (decidualization) and 
form the basic structural matrix of the decidua. The decidua 
rapidly grows and fills up the uterine lumen, causing inflam-
mation, edema, congestion, and hemorrhages. The metrial 
gland is composed of nodular aggregates of heterogeneous 
tissue that develops in the mesometrial triangle in the uter-
ine wall. A schematic view of placental development in rats 
and rabbits is shown in Fig. 58,9.
Normal structure of the chorioallantoic placenta
(1) Fetal part of the placenta
i) Labyrinth zone
The labyrinth zone contains the maternal sinusoids and 
the trophoblastic septa, which are composed of the trilami-
nar trophoblastic epithelium and fetal capillary (Fig. 6). The 
maternal sinusoids full of maternal blood pass between the 
trophoblastic  septa  without  an  endothelium.  The  tropho-
blast epithelium, which comes into direct contact with the 
maternal blood, is referred to as the cytotrophoblast (Fig. 
7). The cytotrophoblast can be easily discerned by its large 
spherical nucleus with prominent nucleolus. It displays nu-
merous microvilli on its surface and contains many pino-
cytotic vesicles at the basal position. Under this trophoblast 
layer, there are two layers of syncytiotrophoblasts (syncy-
tiotrophoblast I and syncytiotrophoblast II from the mater-
nal sinusoid side). Gap junctions are present between these 
two syncytiotrophoblast layers. Basal laminas are located 
between the syncytiotrophoblast II layer and the fetal capil-
lary endothelium. The continuity of these syncytiotropho-
blasts layers provides a placental barrier10. The fetal capil-
laries are the fenestrated type. The pores may contribute to 
the high permeability of the fetal capillary11. Maternal and 
fetal blood come very close together, and most of the mater-
nofetal exchange of substances is carried out in the labyrinth 
zone. The proliferative activity of these trophoblasts peaks 
in midgestation and reduces gradually toward late gestation. 
The labyrinth zone becomes a major part of the placenta 
with pregnancy progression, although other parts of the pla-
centa regress after midgestation (Figs. 5, 8).
ii) Basal zone (Junctional zone)
The  basal  zone  is  comprised  of  three  differentiated 
cells:  (1)  spongiotrophoblast  cells,  (2)  trophoblastic  giant 
cells and (3) glycogen cells (Figs. 2, 6). The spongiotropho-
blast cells are located immediately above the trophoblastic 
giant cell layer and are the main structural component of 
the basal zone. The trophoblastic giant cells located at the 
maternal-placental interface are one of the major endocrine 
cells of the placenta. They synthesize and secrete hormones/
cytokines belonging to the prolactin family12–14 Glycogen 
cells have been reported to appear to be derived from the 
spongiotrophoblasts. However, recent evidence may suggest 
that glycogen cells are distinct from spongiotrophoblasts15,16. 
Glycogen cells are transiently detected in the basal zone in 
Fig.1.  Placental  classification  of  chorioallantoic  placentas  ac-
cording to the relationship established between the chorion 
and uterine wall.  The remaining fetal components include 
three  layers  (trophoblast,  basement  membrane  and  fetal 
capillary), whereas the maternal components are reduced 
step  by  step.  BM,  basement  membrane;  CE,  chorionic 
epithelium  (trophoblasts);  Cy,  cytotrophoblast;  FB,  fetal 
blood; FC, fetal capillary; MB, maternal blood; MC, ma-
ternal capillary; MI, maternal interstitium; Sy, syncytio-
trophoblast; UE, uterine epithelium. (Figure modified from 
that of Burton et al.6)Furukawa, Hayashi, Usuda et al. 97
midgestation. They form multiple small cell masses and gly-
cogen cell islands, and most of them disappear at the end of 
pregnancy. Their biological function is not well understood, 
but it appears to be related with glycogen metabolism. The 
trophoblasts originated from the glycogen cells invade into 
the decidua and metrial gland as interstitial invasion with an 
extensive mushroom-like spreading. The basal zone forms 
channels draining the maternal blood from the placenta, but 
fetal capillaries do not penetrate into the basal zone.
(2) Maternal part of the placenta
i) Decidua
Decidual cells surrounding the blastocyst initially form 
the primary decidual zone, which is avascular and densely 
packed with decidual cells. Subsequently, the more loosely 
packed  decidual  cells  around  the  primary  decidual  zone 
form the secondary decidual zone17 (Fig. 3). The primary 
decidual zone degenerates progressively, and placental and 
embryonic growth slowly replace the secondary decidual 
zone, which is reduced to a thin layer called the decidua 
capsularis and decidua parietalis. The mesometrial decid-
ual cells ultimately form only a thin layer at the base of the 
placenta called the decidua basalis, which is an important 
site for maternal angiogenesis. The decidua basalis includes 
newly developed blood vessels, which play essential roles 
in the development of vascularized decidual-placental inter-
face18. The decidua can produce a wide range of hormones, 
cytokines,  growth  factors  and  immunomodulatory  mol-
ecules involved in the recruitment of the limited but specific 
immune cell populations and growth of the placenta19,20.
ii) Metrial gland
The metrial gland is a normal structure located in the 
mesometrial triangle of the pregnant uterus from early ges-
tation and is fully developed in midgestation, leading to 
regression before parturition21. The metrial gland is com-
posed of a dynamic mixed cell population of decidualized 
Fig. 2.  Structural components and differentiation of the rat placenta.
Fig. 3.  Rat embryo and placenta. (Left - GD 7, right - GD 9, HE 
stain) AC, amniotic cavity; AL, allantois; AM, amnion; 
CH, chorion; ECT, ectoplacental cavity; EPC, ectoplacen-
tal cone; EX, extraembryonic coelom; PAC, proamniotic 
cavity; PDZ, primary decidual zone; SDZ, secondary de-
cidual zone; T, trophectoderm; YC, yolk sac cavity.Toxicological Pathology in the Rat Placenta 98
endometrial stromal cells, uterine natural killer (uNK) cells, 
spinal-shaped arteries and fibroblasts22 (Fig. 6). UNK cells 
belong to a family of natural killer (NK) cells. They are re-
cruited after conception, rapidly divide and differentiate to 
a phenotype that is different from that of the circulating NK 
cells in the metrial gland23. UNK cells play an important 
immunological role in their tolerogenic form24. In addition, 
two types of trophoblasts invade from the fetal part into the 
metrial  gland:  endovascular  trophoblasts  and  interstitial 
trophoblasts. The former enter uterine blood vessels where 
they can replace endothelial cells, and invade to the metrial 
gland from GDs 13–1425. The latter penetrate through the 
uterine stroma from GD 15 and are often situated in peri-
vascular locations26. The endovascular and interstitial tro-
phoblast migrating into the metrial gland express a subset 
of  members  of  the  prolactin  gene  family12.  The  invaded 




The amnion develops from the membrane that crosses 
between the exocoelom and amniotic cavity. Turning of the 
embryo induces the amnion to become enlarged, and then 
the amnion surrounds the whole embryo and forms the am-
niotic raphe after midline fusion29. The amnion consists of a 
Fig. 4.  Rat embryo and placenta (GD 10, HE stain).  AC, amniotic 
cavity; AL, allantois; AM, amnion; CH, chorion; Em, em-
bryo; EPC, ectoplacental cone; EX, extraembryonic coe-
lom; FG, foregut pocket; HG, hindgut pocket; PYS, parietal 
layer of yolk sac; VYS, visceral layer of yolk sac.
Fig. 5.  Placental development schema (Left - rat; right - rabbit).   
Black area shows the fetal part of the placenta. (Figure 
modified from those of Davies et al.8 and Hafez et al.9.)
Fig. 6.  Rat placenta (GD 15, HE stain, lower left, low magnifi-
cation; lower right, decidua basalis; higher left, yolk sac; 
higher middle, labyrinth zone; higher right, basal zone). 
B, basal zone; DB, decidua basalis; FC, fetal capillary; G, 
trophoblastic giant cell; GlyC, glycogen cell; L, labyrinth 
zone; MG, metrial gland; MS, maternal sinusoid; NKC, 
uterine natural killer cells; ST, spongiotrophoblast; T, tro-
phoblast; YS, yolk sac.
Fig. 7.  Rat placental ultrastructure (GD 17).  Cy, cytotrophoblast; 
FB, fetal blood; FC, fetal capillary; MB, maternal blood; 
MS, maternal sinusoid; Sy, syncytiotrophoblast.Furukawa, Hayashi, Usuda et al. 99
single layer of flattened ectodermal cells and some connec-
tive tissue. The amniotic fluid allows free movement of the 
fetus during the later stages of pregnancy and protects it by 
diminishing the risk of injury.
ii)Yolk sac
The yolk sac develops from the membrane lining the 
exocoelom, becomes enlarged and surrounds the whole em-
bryo like the amnion. It is divided into two parts: (1) the 
visceral yolk sac surrounding the embryo with the amnion 
and (2) the parietal yolk sac apposed to the chorion (Fig. 6). 
Because the parietal yolk sac ruptures in midgestation, the 
inside of the visceral yolk sac becomes exposed to the intra-
uterine cavity and is called a reversed yolk sac placenta. The 
yolk sac consists of epithelial cells and mesodermal cells. In 
addition, the parietal yolk sac is lined with Reichert’s mem-
brane, which is a rodent-specific and acellular thin mem-
brane. Blood islands are formed on the surface of the yolk 
sac and subsequently develop into the yolk sac circulation.
Placental circulation
The  maternal  circulation  through  the  placenta  is  as 
follows  (Fig.  9);  the  maternal  arterial  supply  to  the  pla-
centa originates from radial arteries, which enter the uterus 
through the myometrium on the mesometrial side of the 
uterus. Branches of the radial arteries either pass laterally 
through the myometrium or traverse the myometrium and 
enter the metrial gland. Then these arteries branch into sev-
eral spinal-shaped arteries. After traversing the decidua ba-
salis, the spiral arteries converge to form a small number 
of centrally located arterial canals. The arterial canals turn 
around at the surface and lead into the trophoblast-lined ma-
ternal sinusoid spaces in the labyrinth zone. Maternal blood 
drains from the labyrinth through venous sinuses that cross 
the basal zone into the decidua basalis. The venous sinuses 
traverse the outer region of the metrial gland and exit into 
the radial veins outside the myometrium18.
Placental Toxicological Evaluation
Comparison between rats and humans
Generally,  rat  placental  models  have  been  useful  for 
evaluating  the  potential  of  drugs  or  chemicals  that  affect 
human  reproductive  development,  since  there  are  several 
similarities between rats and humans in early placental de-
velopment30. However, there are some differences between 
rats and humans31,32, such as the embryo/fetal period ratio, 
implantation type, function of the yolk sac placenta, placental 
Fig. 8.  Time-dependent change in the thickness of each pla-
cental layer in the rat.
Fig. 9.  Placental circulation in the rat.Toxicological Pathology in the Rat Placenta 100
structure and endocrine synthesis (Fig. 10). Particularly, it is 
suggested that rat placental models are unsuitable for evaluat-
ing the potential effects of drugs or chemicals on the human 
reproductive system and developmental toxicity induced by 
the alteration of placental endocrine functions, because estro-
gen biosynthesis during pregnancy in humans is much differ-
ent from that in rats33. Thus, extrapolating data from rats to 
humans in drug- or chemical-induced developmental toxicity 
should be done based on fully understanding the differences 
and similarities between the rat and human placenta.
Toxicological significance of the placenta
The placenta grows rapidly for a short period with high 
blood flow during pregnancy (Fig. 11) and has multifaceted 
functions, such as its barrier function, nutritional transport, 
drug  metabolizing  activity  and  endocrine  action.  Conse-
quently, the placenta is a highly susceptible target organ 
for drug- or chemical-induced adverse effects, and many 
placenta-toxic agents have been reported (Table 1). On the 
other hand, the dam and fetus have a close relationship with 
each other via the placenta and form the maternal-fetal-pla-
cental unit in mammalian embryonic development. Drug- or 
chemical-induced placental functional depression and inju-
ry subsequently result in abnormal fetal growth or devel-
opment leading to fetal resorption or teratogenicity. Thus, 
Fig. 10.  Placental comparison between the rat and human.
Fig. 11.  Time-dependent  change  in  placental  and  fetal 
weight in the rat.Furukawa, Hayashi, Usuda et al. 101
the placenta is an important organ for evaluating embryonic 
developmental toxicity and understanding its mechanism34. 
However, histopathological examination of the placenta is 
not generally performed, and the placental toxicity index is 
only the placental weight change in rat reproductive toxicity 
studies. As we note below, some drug- or chemical-induced 
placental  histopathological  lesions  have  been  described 
from the point of view of placental weight changes.
Histopathology of the Placenta in the Rat
Lesion associated with an increase in organ weight
(1) Hypertrophy
An  increase  in  placental  weight  is  macropathologi-
cally observed as placental hypertrophy. Firstly, placental 
hypertrophy is induced as a compensatory reaction to IUGR 
under the conditions of a slightly unfavorable maternal en-
vironment, such as maternal hemorrhage35, uterine vessel 
ligation36  and  carbon  monoxide  exposure37.  In  spontane-
ously hypertensive rats, it is induced in response to a poor 
capacity of the uteroplacental unit for transferring glucose 
to  fetuses38.  Drug-  and  chemical-induced  compensatory 
placental hypertrophy is reported in indomethacin-exposed 
rats39 and ethanol-exposed rats40,41. Secondly, placental hy-
pertrophy is detected in the intact uterus with a decreased 
number of corpora luteum, implantation sites and fetuses 
(less than six fetuses in rats)42 as an implantation-related 
reaction. Thirdly, placental hypertrophy is induced as a hor-
mone imbalance reaction, such as estrogen deficiency43,44 
and  ovariectomy  with  estrogen  and  progesterone  treat-
ment45.  Pathological  sequential  changes  of  ketoconazole-
induced placental hypertrophy were recently investigated in 
rats46, as described below.
Ketoconazole, an imidazole antifungal compound, was 
orally administered at doses of 0 and 25 mg/kg/day during 
gestation days (GDs) 12 to 14, and placentas were sampled 
on GDs 15, 17 and 21. There were no effects on the fetal 
mortality rates at each sampling time. No effects on fetal 
weight or no macroscopic fetal abnormalities were detected 
on GD 21. The placentas in the ketoconazole-treated group 
appeared more hypertrophic with increases in their weight, 
diameter and/or thickness from GD 15 onward (Fig. 12). 
Histopathologically, increased thickness was noted in the 
labyrinth zone and basal zone on GDs 17 and 21, while the 
change was already evident in the former zone on GD 15. In 
the labyrinth zone, the mitotic figures of trophoblasts were 
elevated on GD 15. A multiple cystic dilatation of maternal 
sinusoids was observed in some placentas on GDs 15, 17 and 
21. In the basal zone, an increase in the number of spongio-
trophoblasts and clusters of glycogen cells were detected on 
GDs 17 and 21. These changes were particularly remarkable 
at the edge of the basal zone (Fig. 13). In the decidua, there 
were no significant changes in either histology or thickness 
between  the  control  and  the  ketoconazole-treated  group 
during GDs 15 to 21. Estrogen is a known inhibitor of pla-
cental growth, and its deficiency induces placental hyper-
trophy43,44. Ketoconazole inhibits 17α-hydroxylase/C17,20-
lyase  and  aromatase  activity  in  the  steroid  biosynthesis 
pathway47,48. Administration of estrogen inhibits ketocon-
azole induced-placental hypertrophy in rats49. In addition, 
overgrowth of the basal zone is detected in pregnant rats 
ovariectomized and supplied with estrogen and progester-
one45, and this may be induced as a response to hormonal 
imbalance. Therefore, it is suggested that ketoconazole ad-




Labyrinth zone Adrenomedullin antagonist, 1-b-D-arabinofuranosylcytosine, Azacitidine, Aza-
thioprine, Bestatin, Busulfan, Cadmium, Carbon monoxide, Chlorpromazine, 
Cisplatin, Cocaine, Diethylstilbestrol, Estrogen, Ethanol, Ethylnitrosourea, Eto-
poside, Glucocorticoid, Indomethacin, Ketoconazole, Lead acetate, Lipopoly-
saccharide, Mercaptopurine, Methyl methanesulfonate, Streptozocin, Tobacco, 
T-2 toxin, Valproate acid, Vitamin E-deficiency
Basal zone Aromatase inhibitor, Carbenoxolone, Chlorpromazine, Cisplatin, Dexametha-
sone, Glucocorticoid, Ketoconazole, Lead acetate, Lipopolysaccharide, Mer-
captopurine, Methylhydrazine, Methyl methanesulfonate, Methyl parathion, 
Streptozocin, TCDD
Yolk sac Antiserum, Dextran, Dinitrophenol, Ethanol, Iodoacetic acid, Leupeptin, Poly-




Adrenomedullin antagonist, Benomyl, Chlorpromazine, Cisplatin, Cyclospo-
rine, Dibutyltin, Diethylstilbestrol, Doxycycline, Estrogen, Hydroxycarbamide, 
Lipopolysaccharide, L-NAME, Methyl parathion, Mitomycin, Streptozocin, 
Tamoxifen, Tributyltin
Others Bromodeoxyuridine, Difluoromethylornithine, Digoxin, Ergotamine, Hista-
mine, Methotrexate, Organic chlorine agent, Serotonin, VasopressinToxicological Pathology in the Rat Placenta 102
ministration in pregnant rats induces placental hypertrophy, 
which is attributed to the overgrowth of the labyrinth zone 
and basal zone by inhibition of estrogen synthesis and hor-
monal imbalance.
Lesions associated with a decrease in organ weight
A decrease in placental weight is macropathologically 
observed as a small placenta. Mitotic inhibition, apoptosis, 
degeneration and/or necrosis of trophoblasts, which are in-
duced by direct placental injury or nonspecific effects as-
sociated with the conditions of an excessively unfavorable 
maternal environment, result in the inhibition of placental 
development, leading to a small placenta.
(1) Necrosis/degeneration of trophoblasts
Placental  necrosis  macroscopically  shows  thinning, 
discoloration,  hemorrhage,  white  spots  or  adherence  of 
the yolk sac on the chorion surface (Fig. 14). In animal ex-
periments, placental necrosis is induced by such things as 
valproate acid50, chlorpromazine51, glucocorticoid52, strep-
tozotocin53,  cadmium54,  ethanol40,  lead  acetate55,  diethyl-
stilbestrol,  estrogen,  tobacco,  adrenomedullin  antagonist, 
cocaine and vitamin E-deficiency. Histopathologically, pla-
cental necrosis appears more commonly in the trophoblasts 
in the labyrinth zone. There is a reduction in thickness and 
disruption of the trophoblastic septa and irregular dilatation 
of maternal sinusoids with hemorrhage, fibrin deposition 
and inflammatory cell migration, leading to fibrosis and cal-
cification (Fig. 15). In the cadmium-exposed placenta, ex-
pression of metallothionein is detected in the necrotic area 
in the labyrinth zone (Fig. 16), although the main expression 
site of metallothionein is in the decidua and yolk sac sur-
rounding the embryo/fetus throughout gestation56.
Fig. 12.  Placental hypertrophy (Rat, GD 21, left - control; right - 
ketoconazole). Ketoconazole treatment.
Fig. 13.  Thickening of the basal zone (Rat, GD 17, HE stain, left - 
control; right - ketoconazole). Ketoconazole treatment. B, 
basal zone; DB, decidua basalis; GlyC, glycogen cell; L, 
labyrinth zone; ST, spongiotrophoblast.
Fig. 14.  Placental necrosis. Discoloration of the placenta and adher-
ence of the yolk sac to the chorionic surface (Rat, GD 19). 
Cadmium chloride treatment.
Fig. 15.  Calcification and irregular dilatation of the maternal sinu-
soid in the labyrinth zone (Rat, GD 21, HE stain). Lead 
acetate treatment.Furukawa, Hayashi, Usuda et al. 103
Among other specific changes, fetal sideroblastic ane-
mia resulting from hemoglobin synthesis inhibition can in-
duce iron deposition not only in the erythroblasts, but also 
in the trophoblastic septa (Fig. 17).
(2) Cystic degeneration of glycogen cells
Cystic degeneration of glycogen cells is the condition 
describing  abnormal  retention  of  extensive  cytoplasmic 
vacuolation within glycogen cells. The vacuoles contain eo-
sinophilic fibrinous material and polymorphs. The degen-
erated  cells  undergo  cytolysis  and  subsequently  coalesce 
into multiple large cysts that are filled with a homogeneous 
acidophilic mass and multiple clusters of residual glycogen 
cells, macrophages, erythrocytes and cell debris (Fig. 18). 
The degenerated cells did not undergo regression, although 
most glycogen cells disappear at the end of pregnancy in 
normal development. In animal experiments, cystic degen-
eration of glycogen cells is induced by such things as chlor-
promazine51,  streptozotocin53,  6-mercaptopurine  (6-MP)57 
and TCDD58.
(3) Apoptosis/mitotic inhibition of trophoblasts
Placental apoptosis can be detected in both endothelial 
cells, trophoblasts and stromal cells of normal placental tis-
sue, and is believed to be a part of normal developmental 
placental aging59. However, placental apoptosis is also in-
creased in spontaneous abortion, preeclamptic pregnancies, 
post-term  pregnancies  and  pregnancies  complicated  with 
IUGR60–62. It is known that trophoblasts in the fetal part of 
the placenta are a common toxicological target tissue for 
some drugs and chemicals, because they have high prolifer-
ative activity and constitute a major structural component of 
Fig. 16.  Left - extensive necrosis in the labyrinth zone (Rat, GD 
19, HE stain). Right - expression of metallothionein in cad-
mium-damaged trophoblasts in the labyrinth zone (Rat, 
GD 19, metallothionein immunostain). Cadmium chloride 
treatment.
Fig. 17.  Iron  deposition  in  fetal  erythroblasts  and  trophoblastic 
septa in the labyrinth zone (Rat, GD 13, Berlin blue stain). 
Compound A treatment.
Fig. 18.  Thickening of the basal zone with cytolysis of glycogen 
cells (  ↑) (Rat, GD 21, HE stain). Treatment with 6-MP.
Fig. 19.  Small placenta (Rat, GD 21, left - control; right - busulfan). 
Busulfan treatment.Toxicological Pathology in the Rat Placenta 104
the fetal part of the placenta. Trophoblast apoptosis leads to 
a lack of cell populations required for later normal histogen-
esis, resulting in a small placenta. In animal experiments, 
placental apoptosis is induced by such things as glucocor-
ticoid52,63,  lipopolysaccharide64,  T-2  Toxin65,  anoxia  and 
some anticancer drugs. Particularly, anticancer drugs, such 
as ethylnitrosourea66 and 1-b-D-arabinofuranosylcytosine67 
induce trophoblastic apoptosis and/or mitotic inhibition by 
an increase in p53 expression in response to DNA damage. 
However, anticancer drug-induced histopathological lesions 
differ depending on the drugs and the exposure period. The 
pathological sequential changes of the small placenta in rats 
treated with busulfan68, 6-MP57 and cisplatin (not yet pub-
lished) were recently investigated, as described below.
Busulfan, an alkylating agent, is a known teratogen, 
inducing  anophthalmia,  microtia,  microrostellum,  micro-
gnathia, microabdomen, micromelia, oligodactylia, brachy-
dactylia, vestigial tail, short tail, anasarca, microencephaly, 
microphthalmia, and cataract in rats69. In the present study, 
busulfan was intraperitoneally administered at doses of 0 
and 10 mg/kg/day during GDs 12 to 14, and placentas were 
sampled on GDs 13.5, 14.5, 15, 16 and 21. There were no 
effects on the fetal mortality rates at each sampling time. 
Macroscopically,  fetal  dwarfism  was  observed  with  re-
duced body weight and kinky tail in the busulfan-treated 
group. The placentas decreased in weight and were shown 
macroscopically to be small and thin with scattered white 
spots and a white peripheral rim on GD 21 (Fig. 19). His-
topathologically,  busulfan  treatment  provoked  increased 
apoptosis (Fig. 20) and decreased mitotic activities of the 
trophoblasts in the labyrinth zone on GDs 13.5, 14.5, 15 and 
16. Degeneration and necrosis of the trophoblasts, a diminu-
tion in thickness of the trophoblastic septa with deposition 
of calcium and irregular dilation of the maternal sinusoids 
were scattered in the labyrinth zone (Fig. 20), although there 
were no conspicuous changes in the basal zone. A reduc-
tion in diameter in the labyrinth zone was detected on GD 
21. From these results, it is suggested that busulfan induces 
cell cycle arrest in the G1/G2-phase and DNA damage in 
trophoblasts, leading to apoptosis and mitotic inhibition in 
the labyrinth zone. It is reported that the proliferative period 
of spongiotrophoblasts in the basal zone diminishes earlier 
and is narrower than that of trophoblasts in the labyrinth 
zone70. Therefore, the difference in sensitivity to busulfan 
between the labyrinth zone and the basal zone appears to 
be attributed to the difference of each cellular proliferation 
period with advancing pregnancy. It is considered that bu-
sulfan administration in pregnant rats induces growth arrest 
of the labyrinth zone, leading to a small placenta.
The purine antimetabolite 6-MP is a known teratogen, 
inducing limb defects, micrognathia, ventral hernia, skel-
etal, urogenital, CNS and ocular anomalies, cleft palate and 
diaphragmatic hernia. In the present study, 6-MP was intra-
peritoneally administered at doses of 0 and 60 mg/kg/day 
during GDs 11 to 12, and placentas were sampled on GDs 
13, 15 and 21. The fetal mortality rates increased up to 40%, 
and some malformations of fetuses (as referred to above) 
were detected on GD 21 in the 6-MP-treated group. The fe-
tal and placental weights were decreased on GDs 15 and 21. 
Macroscopically, the placentas on GD 21 were small, brittle 
and thin with a white peripheral rim (Fig. 21). Histopatho-
logically, 6-MP treatment mainly evoked decreased mitosis 
on GDs 13 and 15, and increased apoptotic cells on GDs 
13, 15 and 21 in the labyrinth zone (Fig. 22). There were 
decreased trophoblasts, a diminution in the thickness of the 
trophoblastic septa and irregular dilatation of maternal si-
nuses with deposition of fibrin on GD 21 (Fig. 22). In the 
basal  zone,  there  were  decreased  mitotic  spongiotropho-
blasts on GD 13 and increased apoptotic cells on GD 21. 
PAS-positive material in the spongiotrophoblasts on GD 15 
was still detected in the 6-MP-treated group, but not in the 
control group (Fig. 23). The clusters of glycogen cells con-
sisted of small and irregular-shaped cells as compared with 
the controls. Because most of the PAS-positive material in 
the spongiotrophoblasts disappears after GD 14 in normal 
development8, spongiotrophoblast development and differ-
entiation appear to be delayed in the 6-MP-treated group. 
Furthermore,  cytolysis  of  glycogen  cells  (cystic  degen-
eration of glycogen cells), apoptosis and a subinvolution of 
spongiotrophoblasts were observed on GD 21 (Fig. 18). The 
thickness of the basal zone was increased on GD 21, as a 
result of the cystic degeneration of glycogen cells, although 
the labyrinth zone was reduced in diameter on GDs 15 and 
21. Therefore, it is considered that 6-MP administration in 
pregnant rats induces growth arrest of the labyrinth zone, 
leading to a small placenta. In addition, 6-MP provokes a 
delay in the developmental process of the basal zone and 
cystic degeneration of glycogen cells.
Cisplatin, a platinating agent, is considered to be highly 
embryo lethal and growth retardant but to not be a teratogen 
in rats and rabbits71. Cisplatin can pass through the placen-
tal barrier and is a transplacental carcinogen for the fetal 
liver, kidney, nervous system and lung in pregnant rats72. In 
the present study, cisplatin was intraperitoneally adminis-
tered at 2 mg/kg/day during GDs 11 to 12 (GD11,12-treated 
group) or GDs 13 to 14 (GD13,14-treated group), and the 
placentas were sampled on GDs 13, 15, 17 and 21. Fetal mor-
tality rates were increased up to 65% from GD 17 onward, 
and fetal weights were decreased on GD 21 in the GD11,12-
treated group. However, there were no effects on fetal mor-
tality rates and fetal weight in the GD13,14-treated group. 
There were no macroscopic fetal abnormalities on GD 21 in 
either treated groups. A reduction in placental weight was 
detected from GD 15 onward, and the placentas on GD 21 
were macroscopically small and thin with a white peripheral 
rim in both treated groups. Histopathologically, an increase 
in apoptotic cells was detected in the labyrinth zone during 
the experimental period and in the basal zone on GD 21, and 
then labyrinth zone hypoplasia was induced in the GD13,14-
treated group. By contrast, an increase in apoptotic cells 
was detected on GDs 13, 15 and 17 in the labyrinth zone, 
and during the experimental period in the basal zone (Fig. 
24), and then hypoplasia of the labyrinth and basal zones 
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tion, a marked decrease in glycogen cell islands in the basal 
zone was also detected on GDs 15 and 17 in this group (Fig. 
26). There was a reduction in interstitial invasion of glyco-
gen cell-like trophoblasts along the arterial canal into the 
metrial gland on GD 15 (Fig. 26) and metrial gland hypo-
plasia from GD 17 onward (Fig. 27). Consequently, tropho-
blastic apoptosis in the basal zone, including pre-glycogen 
cells  leads to a lack of the cell populations required for nor-
mal development into glycogen cells and then inhibits the 
interstitial invasion of glycogen cells into the decidua and 
metrial gland, resulting in metrial gland hypoplasia. On the 
other hand, in the 6-MP-administrated rats on GDs 11 and 
12, there was no detected basal zone hypoplasia, although 
labyrinth zone hypoplasia was induced57. These results sug-
gest that the basal zone has not only an earlier and narrower 
sensitive period but also higher specificity for the toxicity of 
anticancer drugs, compared with the labyrinth zone. There-
fore, it is considered that cisplatin administration in preg-
nant rats induces trophoblast apoptosis in the labyrinth and 
basal zones, leading to a small placenta. In addition, metrial 
gland hypoplasia occurs secondary to the failure of glyco-
gen cell island development.
Lesions associated without changes in organ weight
(1) Hypoplasia of the decidua/metrial gland
Hypoplasia  of  the  decidua  and  metrial  gland  is  not 
reflected  in  the  placental  weight,  because  placentas  are 
stripped off between the basal zone and the decidua basa-
lis at the time of placental weight measurement in devel-
opmental toxicity studies. Hypoplasia of the decidua and 
metrial gland is induced by such things as decidualization 
inhibition,  reduction  in  the  proliferative  activity  of  uNK 
cells and inhibition of interstitial trophoblast invasion into 
the metrial gland. In animal experiments, hypoplasia of the 
Fig. 20.  Left - apoptosis of trophoblasts in the labyrinth zone (Rat, 
GD 15, TUNEL stain). Right - degeneration and necrosis 
of trophoblasts with deposition of calcium in the labyrinth 
zone (Rat, GD 21, HE stain). Busulfan treatment.
Fig. 21.  Small placenta (Rat, GD 21, left - control; right - 6-MP). 
Treatment with 6-MP.
Fig. 22.  Left - Apoptosis of trophoblasts in the labyrinth zone (Rat, 
GD 13, HE stain). Right - decreased number of tropho-
blasts, a reduction in thickness of trophoblastic septa and 
irregular dilatation of maternal sinusoids with deposition 
of fibrin (Rat, GD 21, HE stain). Treatment with 6-MP.
Fig. 23.  Increased  PAS-positive  material  in  spongiotrophoblasts 
around clusters of glycogen cells (Rat, GD 15, PAS stain, 
left - control; right - 6-MP). Treatment with 6-MP.Toxicological Pathology in the Rat Placenta 106
decidua and metrial gland is induced as a result of inhibition 
of matrix metalloproteinases by doxycycline73, suppression 
of decidual cell proliferation by benzimidazole fungicides74, 
hydroxyurea75,  diethylstilbestrol,  mitomycin  and  ovariec-
tomy76, decreased progesterone levels resulting from by tri-
butyltin77 and inhibition of interstitial trophoblast invasion 
by cisplatin (described above). The pathological sequential 
changes  in  tamoxifen-induced  metrial  gland  hypoplasia78 
were recently investigated in rats, as described below.
Tamoxifen,  a  nonsteroid  selective  estrogen  receptor 
modulator, has been widely used for therapy of estrogen-re-
ceptor-positive breast cancer. In the present study, tamoxifen 
was intraperitoneally administered at doses of 0 and 2 mg/
kg/day during GDs 8 to 10, and placentas were sampled on 
GDs 11, 13, 15, 17 and 21. The fetal mortality rates in the 
tamoxifen-treated group were increased up to approximate-
ly 50% from GD 15 onward. However, there were no effects 
on the weights of live embryos/fetuses and their placentas at 
each sampling time, and there were no macroscopic abnor-
malities in the fetuses and placentas on GD 21. Histopath-
ologically, the size of the metrial gland in the tamoxifen-
treated group was reduced at all sampling times compared 
with the control group (Fig. 28). The spiral arteries appeared 
less well developed in the hypoplastic metrial gland (Fig. 
28). The uNK cells around the spiral arteries were decreased 
from GD 13 onward in the tamoxifen-treated group (Fig. 
29). The number of mitotic cells that appeared to be uNK 
cells was lower on GDs 11 and 13 in the tamoxifen-treat-
ed group. There were no obvious changes in the labyrinth 
zone, basal zone or decidua basalis. It is known that the de-
velopment of the metrial gland is a part of decidualization, 
which is a sequential process of growth and differentiation 
Fig. 24.  Apoptosis of spongiotrophoblasts in the basal zone (Rat, 
GD 15, TUNEL stain). Cisplatin treatment.
Fig. 25.  Basal zone hypoplasia (Rat, GD 21, HE stain, left - control; 
right - cisplatin). Cisplatin treatment. B, basal zone; DB, 
decidua basalis; L, labyrinth zone.
Fig. 26.  Decrease in glycogen cell islands and inhibition of intersti-
tial invasion of glycogen cell-like trophoblasts into metrial 
glands (Rat, GD 15, HE stain, left - control; right - cispla-
tin). Cisplatin treatment. AC, arterial canal; B, basal zone; 
D, decidua basalis; GlyC, glycogen cell; L, labyrinth zone; 
M, metrial gland.
Fig. 27.  Metrial gland hypoplasia (Rat, GD 21, HE stain, left - con-
trol;  right  -  cisplatin).  Cisplatin  treatment.  MG,  metrial 
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of uterine stromal cells and uNK cells, and remodeling of 
the extracellular matrix and maternal vasculature79. In NK 
gene knock-out mice (TgE26 mice), there was no develop-
ment of the mesometrial triangle area into the metrial gland, 
and the reproductive performance was very poor (mortal-
ity: 40%), suggesting that uNK cells are necessary for pla-
cental growth and gestational success80. The uNK cells are 
involved in a role of regulation and restructuring of spiral 
arteries in the metrial gland23,81, and maternal immune tol-
erance forms toward invading trophoblast cells at the mater-
nal-fetal interface24,27. Alterations of uNK cell function and 
inadequate remodeling of spiral arteries play an important 
role in preeclampsia, which leads to high maternal blood 
pressure,  elevated  concentrations  of  urinary  protein  and 
poor fetal growth82. Therefore, it is suggested that the an-
tiestrogen effect of tamoxifen inhibits the proliferation of 
decidualized endometrial stromal cells in the metrial gland 
and leads to metrial gland hypoplasia resulting from inhi-
bition of proliferative activity of uNK cells and defective 
development of spiral arteries. Tamoxifen-induced embryo/
fetus-toxicity might be associated with the immune toler-
ance deficiency caused by decreased uNK cells in metrial 
gland hypoplasia and/or preeclampsia caused by defective 
development of spiral arteries.
(2) Vacuolar degeneration of the yolk sac epithelium
Vacuolar  degeneration  of  the  yolk  sac  epithelium  is 
induced  and  caused  by  the  accumulation  of  indigestible 
material in the vacuolar system by inhibition of intralyso-
somal proteolysis83. Histopathologically, the visceral yolk 
sac  epithelium  contains  numerous  accumulated  vacuoles 
(Fig. 30). In animal experiments, the vacuolar degenera-
tion of the yolk sac epithelium is induced by such things 
Fig. 28.  Marked metrial gland hypoplasia with less well develop-
ment of spiral arteries (Rat, GD 11, HE stain, left - control; 
right - tamoxifen). Tamoxifen treatment. DB, decidua basa-
lis; MG, metrial gland.
Fig. 29.  Decrease in uNK cells with clear cytoplasm and PAS-posi-
tive granules around spiral arteries (Rat, GD 13, PAS stain, 
left - control; right - tamoxifen). Tamoxifen treatment. SA, 
spiral artery.
Fig. 30.  Vacuolar degeneration of the yolk sac epithelium (Rat, GD 
15, HE stain). Trypan blue treatment.
Fig. 31.  Increased in expression of GLUT3 (  ↑) along trophoblastic 
septa (Rat, GD 17, GLUT3 immunostain, left - control; 
right - 6MP). Treatment with 6MP.Toxicological Pathology in the Rat Placenta 108
as trypan blue83, Triton WR-133984, polyvinylpyrrolidone84, 
dextran84, sucrose84, leupeptin85, somatomedin inhibitor86, 
ethanol87 and dinitrophenol88. Before the formation of the 
chorioallantoic placenta, the yolk sac plays a role in the up-
take and transport of nutrients from the dam to the develop-
ing embryo2,3. Particularly, in the rodent, the functions of 
the yolk sac placenta are maintained until just before par-
turition. Thus, yolk sac epithelial damage is correlated with 
embryonic malformations and fetal developmental toxicity.
Relationship between Fetal Intrauterine Growth 
Restriction and Small Placenta
Placenta  size,  architecture,  developmental  and  patho-
logical processes, and metabolic interaction with the fetus co-
operate with placental transport and metabolic mechanisms 
to qualitatively and quantitatively affect placental-fetal nu-
trient exchange89. In humans, a positive correlation between 
placental weight and birth weight is observed in normal and 
large-for-gestational-age infants90. Thus, it is commonly be-
lieved that placental size and fetal weight are directly inter-
related91. However, it has not been clear how the changes in 
placental size and function relate to changes in fetal meta-
bolic demands92. The effect of placental size on IUGR was 
recently investigated in the placentas of rats exposed to 6-MP 
at various points of gestation93, as described below.
In the present study, 6-MP was administered orally 
at 0 and 60 mg/kg/day on GD 9, 11, 13 or 15, and the pla-
centas were sampled on GDs 17 and 21. The main patho-
logical findings in all treated groups were fetal resorption 
and IUGR with or without some malformations and a small 
placenta caused by mitotic inhibition and apoptosis of tro-
phoblasts in the labyrinth zone. Complete fetal resorption 
was observed in most litters with the treatment on GD 9. 
The most remarkable response of small placenta and fetal 
abnormalities to 6-MP treatment occurred in the litters with 
the treatment on GD 11. However, the litters in a quarter 
of the dams with the treatment on GD 11 showed no feto-
toxicity despite a 25% decline in placental weight and an 
increased fetal–placental weight ratio. Histopathologically, 
the expression of glucose transporter GLUT3 was increased 
in the trophoblastic septa in all treated groups, and this was 
particularly remarkable considering the proliferation of tro-
phoblasts in the above litters, which showed an increased 
fetal-placental weight ratio (Fig. 31). It is known that one of 
the major nutrient transport functions of the placenta is to 
ensure adequate transfer of glucose from the maternal to fe-
tal circulation. Glucose transfer across the placental barrier 
is crucial for fetal development. A common characteristic of 
pregnancies with IUGR is relative fetal hypoglycemia, and 
a small placenta per se is the major limitation on placen-
tal glucose transfer from the dam to the fetus94. Placental 
functions are highly adaptable and can change in response 
either to the maternal environment or to defects within the 
placenta itself, indicating either the capacity for placental 
nutrient transport to increase or the capacity for the fetus 
to extract nutrients from the umbilical circulation95,96. From 
these results, it is suggested that the elevated GLUT3 ex-
pression may reflect an attempt to increase the maternal-
to-fetal glucose transport supply in order to compensate for 
the deterioration of placental function in the 6-MP-exposed 
small placenta and contribute to normal fetal growth and 
development. Therefore, it is considered that normal fetal 
growth and development can be maintained as a result of an 
increase in the expression of glucose transporter as adaptive 
change, even if the placental weight decreases by approxi-
mately 25% in 6-MP exposed rats.
Conclusion
The fully formed placenta plays a major role in the 
maintenance of nutrition for the fetus and in the secretory 
and essential regulatory functions for the maintenance of 
pregnancy during the fetal period. However, despite the pla-
centa being one of the important organs for evaluation of 
risks for the dam and embryo, the placental toxicity index 
in  developmental  toxicity  studies  is  the  placental  weight 
change alone. As previously described, the pathogenesis of 
placental lesions show various and complex features, be-
cause the constitutive cells of the placenta originate from 
embryonic and maternal tissue, proliferate rapidly, differ-
entiate and undergo morphological changes in close rela-
tion to each other according to the development sequence 
in a short pregnancy period. Even if the placental weight 
is reduced, the induced lesions are histopathologically dif-
ferent depending on the toxicants and the exposure period. 
In addition, normal fetal growth and development can be 
maintained as a result of the adaptive change, as long as the 
placental growth inhibition is within the allowable range. It 
is difficult to detect pathological changes in the decidua and 
metrial gland by placental weight assessment. Thus, placen-
tal weight assessment appears not to be enough to evaluate 
placental toxicity, and reproductive toxicity studies should 
pay  more  attention  to  placental  histopathological  evalu-
ation on a case-by-case basis. Moreover, placental histo-
pathological evaluation should comprehensively reveal the 
time-dependent changes in each placental tissue in view of 
the drug or chemical-exposure period and normal placental 
development. These detailed histopathological approaches 
to the pathogenesis of placental toxicity are considered to 
provide an important tool for understanding the mechanism 
of teratogenicity and developmental toxicity with particular 
regard to embryo lethality and delayed development, and 
could benefit reproductive toxicity studies.
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